Table 1. Sample cohort.
| Sample Type | N | Age, mean (Range) | Male % | Female % | Basis for Diagnosis |
|---|---|---|---|---|---|
| SARS-CoV-2 positive | 303 | 56 (17–87) | 41% | 59% | RT-PCR |
| SARS-CoV-2 negative | 296 | 51 (12–88) | 45% | 55% | RT-PCR |
| Systemic Lupus Erythematosus (SLE) | 26 | 36 (26–68) | 35% | 65% | Physician |
| Lyme disease | 20 | 47 (19–84) | 45% | 55% | Physician |
| CMV | 4 | 25 (18–31) | 75% | 25% | RT-PCR |
| Hepatitis C | 20 | 54 (21–89) | 45% | 55% | RT-PCR |
| Syphilis | 6 | 53 (33–73) | 33% | 67% | RT-PCR |
| Celiac disease | 26 | 48 (18–75) | 38% | 62% | Biopsy |
| Rheumatoid arthritis | 26 | 52 (21–84) | 46% | 54% | Physician |
| Healthy Controls (Prior to outbreak) | 4502 | 49 (17–90) | 43% | 57% | January–April 2019 |
| CROSS REACTIVITY CONTROLS | |||||
| ANA (Anti-Nuclear Antibodies) | 79 | 57 (8–90) | 34% | 66% | Serology |
| HBV antibodies | 18 | 47 (19–82) | 42% | 58% | Serology |
| HCV antibodies | 14 | 48 (22–62) | 50% | 50% | Serology |
| Influenza A antibodies | 42 | 45 (20–65) | 27% | 73% | Serology |
| Influenza B antibodies | 26 | 48 (22–75) | 38% | 62% | Serology |
| Respiratory Syncytial Virus antibodies | 52 | 51 (18–78) | 38% | 62% | Serology |
| Common Human Coronavirus | 27 | 32(15–66) | 52% | 48% | RT-PCR |
| Adenovirus | 4 | 47 (18–71) | 50% | 50% | Serology |
| Coxsackie Virus | 31 | 52 (36–78) | 38% | 62% | Serology |
| Echovirus | 28 | 44 (22–61) | 40% | 60% | Serology |
| Poliovirus | 11 | 50 (18–80) | 48% | 52% | Serology |
| Rhinovirus | 4 | 48 (24–66) | 50% | 50% | Serology |